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The concentrations of tumor necrosis factor (TNF) produced by human peripheral blood 
mononuclear cells (MNC) were measured using a radioimmunoassay (RIA) for human 
TNF. This was developed using a rabbit antiserum against human recombinant TNF (Hu 
rTNF), and Hu rTNF labeled with Na125l by a modification of the chloramine T method.
This RIA does not detect human lymphotoxin, interleukin-1 alpha or beta, interleukin 2, 
interleukin 6, interferon alpha or gamma, granulocyte-macrophage-colony stimulating 
factor, and C5a des arg. A good correlation (r = 0.89) was found between the RIA and 
the cytolytic bioassay for TNF. The sensitivity of the RIA is between 3 and 78 pg/ml 
(median 11 pg/ml).
The mean concentration of TNF in 24-h culture supernatants of human MNC exposed 
to different concentrations of lipopolysaccharide (LPS) was found to increase in dose- 
dependent fashion and then level off between 50 and 100 ng/ml. The concentrations of 
IL-1 beta and alpha detected by specific RIAs in these supernatants were between 0.2 
and 19 ng/ml and 0.04 and 1 ng/ml, respectively. The amount ot TNF produced by human 
MNC in vitro was determined in a cohort of 50 normal volunteers. Without exogenous 
stimuli, TNF concentrations were almost always below the detection limit; with 0.5 ng/ 
ml LPS, the median concentration of TNF was 2 ng/ml, and with PHA the median was
3.8 ng/ml. In cultures performed in the presence of indomethacin significantly ( p < 0.005) 
more TNF was produced.
Using this RIA, we could detect TNF in the circulation of mice injected with Hu rTNF.
When plasma samples of patients with febrile illnesses were added directly to the RIA,
TNF was not detectable, with the exception of patients with malaria.
These studies demonstrate the range and sensitivity of LPS-induced and mitogen- 
induced production of immunoreactive TNF by human MNC in vitro without interference 
of similar cytokines in bioassays.
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INTRODUCTION
T u m o r  necrosis  fac tor-a lpha (T N F ,  synonym  cachec- 
tin) is a cy tokine  with a wide variety o f  actions [l ]. A 
n u m b e r  o f  activities o f  the molecule  are  shared  with 
ano the r  cy tok ine ,  in te r leuk in -1 (IL) (a  and 0). For  in­
stance the py rogen ic  effect;  the ability to induce an acute- 
phase  response ;  and the s t imulatory  effects on f ibro­
blasts,  os teoclas ts ,  endothelia l ,  and synovial cells are 
c o m m o n  to both m olecules  [2 -4 ] .  Recent studies also 
indicate that there  is a s trong synerg ism  be tw een  T N F  
and IL-1 0  [5], and it has becom e apparen t  that T N F  
st imulates  the p roduc t ion  o f  IL-1 both in vivo and in
vitro  [2].
M ea su re m e n t  o f  T N F  in culture  supernatant  has fo­
cused  on the cytotoxicity  assay. H ow ever ,  IL-1 and o ther
© 1988 Alan R. Liss, Inc.
subs tances  that are  often present  with T N F  in cell su p e r ­
natants affect the T N F  cytotoxicity  assay, since IL-l  also 
exhibits  cy to toxic  p roper t ies  [6]. In the present  paper  we 
have em p lo y ed  a rad io im m unoassay  (RIA) for T N F  se­
cre ted  by hu m an  m o n o n u c lea r  cells in vitro under  a 
variety  o f  condit ions .  F u r th e rm o re ,  we co m p are  the c o n ­
cen tra t ions  o f  T N F  to IL - l  0  and IL-1 a  using endotoxin 
( l ipopo lysacchar ide ,  LPS) as a stimulus.
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MATERIALS AND METHODS 
Preparation of the Antiserum
Female New Zealand white rabbits (Pine Acres, Bur­
lington, VT) were immunized with 50 ¿ig recombinant 
human tumor necrosis factor (Hu rTNF), obtained from 
three sources: Genentech Inc. (South San Francisco, CA), 
Cetus Corp. (Emeryville, CA), and Biogen (Cambridge, 
MA). The initial immunization took place in complete 
Freund's adjuvant, using 12 intradermal injections. After 
8 weeks the animals were boosted monthly with 50 ¿ig 
TN F in incomplete Freunds’s adjuvant intramuscularly. 
Unfractionated serum was used as anti-TNF antiserum. 
Cross-reactivity of this antiserum with human recombi­
nant interleukin-1 ß  (Cistron Technology Inc., Pine 
Brook, NJ), human recombinant interleukin-1 a  (kindly 
provided by Dr Alan Shaw, Biogen, Geneva, Switzer­
land), human recombinant interleukin-2 (Cetus Corp.), 
human recombinant interleukin-6 (Genetic Institute, 
Cambridge, MA), human recombinant interferon alpha 
(Schering Corp., Kenilworth, NJ), human recombinant 
interferon gamma (Schering Corp.), human recombinant 
granulocyte-macrophage-colony stimulating factor (Ge­
netics Institute, Cambridge, MA), human C5a des arg 
(kindly provided by Dr KB Yancey, Uniformed Services 
University of the Health Sciences, Bethesda, MD), hu­
man recombinant lymphotoxin, and murine recombinant 
TN F (both kindly provided by Dr MA Palladino Jr, 
Genentech, Inc.) was investigated in various concentra­
tions in the radioimmunoassay as described below.
Radiolabeling Hu rTNF
Hu rTNF was labeled using a modification of the 
chloramine T method [7]; 5 ¿¿g Hu rTNF (500 /zg/ml) 
and 0.5 mCi N a ,2:>l (100 mCi/ml, New England Nuclear, 
Boston, MA) were added to 10 ¿¿1 of 0.5 M sodium 
phosphate buffer (pH 7.4) and mixed. Next, 10 ¿¿g chlor­
amine T (Sigma Chemical Co, St Louis, MO; 2.5 mg/ml 
in 0.25 M sodium phosphate buffer, pH 7.4) were added 
and mixed by gently pipetting for exactly 10 s. The 
reaction was terminated by adding 100 pig of the reducing 
agent sodium metabisulfite (Sigma; 5 mg/ml in 0.25 M 
sodium phosphate buffer, pH 7.4). Finally, 300 ¡jl 1 of 
BSA-buffer containing 0.01 M phosphate buffered sa­
line, 0.25% bovine serum albumin (BSA, Sigma), and 
0.05% sodium azide) was added. The radiolabeled ma­
terial was chromatographed on a Sephadex G50 (fine) 
(Pharmacia, Piscataway, NJ) column (0.8 x  30 cm) to 
separate the radiolabeled protein from the free 1251. BSA- 
buffer was used to equilibrate and to run the column. 
Twenty-five fractions of 0.7 ml were collected. The 
radioactivity o f  aliquots of these fractions was deter­
mined in a gamma counter. Next, small aliquots from 
each fraction were incubated with a 1:100 dilution of the 
anti-TNF antiserum for 18 h at room temperature, and 
then precipitated with 6 % (w/v) polyethylene glycol 8000
(Fisher Scientific Company, Fair Lawn, NJ) and 1 % 
sheep antirabbit IgG (Sigma).
The homogeneity of the radiolabeled TNF was deter­
mined with SDS-polyacrylamide gel electrophoresis 
(17%) [8] and autoradiography. The biological activity 
o f  the radiolabeled TNF was measured in the bioassay 
for TNF (see below). The specific activity of the labeled 
TN F was calculated assuming 75% recovery and using 
the known efficiency of the gamma counter.
Titration of Anti-TNF Antiserum
Aliquots of the radiolabeled TNF containing 15,000 
cpm were diluted in 100 /¿I BSA-buffer and incubated 
with serial twofold dilutions of the anti-TNF antiserum 
for 18 h at room temperature, and then precipitated with 
an equal volume of 6 % polyethylene glycol and 1% 
sheep antirabbit IgG.
Radioimmunoassay for TNF
Both standards and samples were assayed in duplicate 
or in some experiments in triplicate in 10 x  75-mm 
polystyrene tubes (Stockwell Scientific, Walnut, CA). In 
every assay, 12 standards of Hu rTNF (5,000, 2,500, 
1,250, 625, 313, 157, 79, 40, 20, 10, 5, and 0 pg/ml)
were employed. Depending on the nature of the samples, 
the standards were diluted in either human serum, urine, 
or BSA-buffer. On the first day of the assay, 100 ¿¿1 of 
the anti-TNF antiserum (diluted in order to precipitate 
40% of the radiolabeled TNF) was added to 100 /xl of the 
standards or to 100 /xl of the samples. To determine the 
nonspecific binding (NSB), 100 /¿I BSA-buffer was added 
to a standard containing no TNF. On the same day, 300 
Ijl 1 o f  BSA-buffer containing 0.3% heat-inactivated nor­
mal rabbit serum was added to each tube. After vortex- 
ing, the tubes were incubated at room temperature. The 
next day, 100 /zl of BSA-buffer containing 10,000 cpm of 
radiolabeled TNF were added to each tube, and after 
vortexing, again incubated at room temperature. On the 
third day, 700 ¿¿1 of BSA-buffer containing 9% of poly­
ethylene glycol 8000 and 1.4% sheep antirabbit IgG were 
added. The tubes were vortexed and then centrifuged at
l,500g for 15 min. Thereafter, the supernatants were 
decanted, and the tubes were kept inverted and allowed 
to dry for at least 15 min before being counted. The mean 
cpm of duplicate or triplicate standards were calculated 
and the counts of the NSB subtracted. All standards were 
then expressed as a percentage of the standard containing 
no TNF (zero standard). The values obtained were con­
verted using the logit transformation, according to the 
formula logit x =  ln(x/100 —x). The logit values were 
plotted on the x-axis against the concentrations on a 
logarithmic y-axis. An exponential curve fit was per­
formed, using Cricket graph (Cricket Software, Philadel­
phia, PA) on an Apple Macintosh Plus computer. The 
formula for the curve fit obtained was used to calculate
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the “ backfi t” o f  the standard curve and to determine the 
concentration o f  T N F  in samples. Values < 9 5 %  of  the 
zero standard (logit x <  2.94) were accepted.
Radioimmunoassays for IL-1 a  and ¡3
Radioimmunoassays for human IL-1 (3 [9] and a  [10] 
were performed as described.
Bioassay for TNF
To measure the T N F  activity in a bioassay, standards 
and samples were incubated with L929 cells (ATCC
search Triangle Park, NC) was added. Cultures were 
performed either with or without 0.5 fig/ml indomethacin 
(Sigma). After 24 h o f  culture at 3 7 °C in a water- 
saturated atmosphere with 5% C 0 2, either the culture 
supernatants or  the contents o f  each well after three 
freeze-thaw cycles were harvested, centrifuged at 10,000g 
(Micro centrifuge, Fisher Scientific), for 1 min and fro­
zen at —70°C  until assay.
Hu rTNF in Mice
T N F  concentrations were measured in EDTA-treated
CCL1) as described by Flick and Gifford [11]. In short, plasma obtained by cardiac puncture at various time
the L929 cells were cultured in RPMI 1640 containing 2 
m M  L-glutamine and 10% heat-inactivated fetal calf 
serum (all from microbiological Associates, Walkers- 
ville, MD) in 7 5 -c n r  polystyrene tissue culture flasks 
(Falcon, Oxnard,  CA) and split every 3 days. One day 
after subculture, the nonadherent cells were decanted 
after vigorous shaking o f  flask. After adding fresh m e­
dium the adherent cells w'ere scraped with a policeman 
(Costar, Cambridge,  M A), and after washing (450g, 10 
min), 100-^1 aliquots o f  the cell suspension (5 x  105/ml) 
were pippetted in 94 wells o f  a 96-well flat-bottom 
microtiterplate (A/S Nunc, Roskilde, Denmark).  After 
incubation overnight (37°C , 5% C 0 2), the culture super­
natants were decanted, and 100 /¿I o f  15 /xg/ml actino- 
mycin D (Sigma) in saline, and 100 fi\ o f  RPMI 1640 
with 10% fetal calf  serum w'as added to each w'ell. After 
adding 100 /xl o f  either medium (control), T N F  standards 
or samples to at least quadruplicate wells, the plates were 
reincubated. The next day, the supernatants w'ere de­
canted and the wells were rinsed with saline. After stain­
ing o f  the cells w'ith 0.1 % (w/v) crystal violet (Sigma) in 
100% methanol for 20 min, the plates were rinsed with 
tap water and dried. Absorbance (A) was measured in an 
ELISA reader at 595 nm and the percentage o f  cytotox­
icity determined as
[ ( A COn tro l— A s a m p le V A c o n tro l ]  ^  1 0 0 .
Isolation and Culture of Human Mononuclear Cells
Heparinized blood (10 U heparin/ml blood) from hu­
man volunteers was diluted threefold in 0.15 M saline 
and centrifuged on pyrogen-free Ficoll Hypaque. The 
mononuclear  cells (M NC) o f  the interphase were washed 
three times in ultrafiltered [ 12] RPMI 1640 supplemented 
with 2 m M  L-glutamine, 100 U/ml benzylpenicillin, 100
f.ig/ml streptomycin, 10 mM HEPES (all from M icro­
biological Ass. ,  Walkersville, M D), and 1% heat-inacti- 
vated AB serum. A volume of  100 /xl o f  cell suspension 
(final concentration 2.5 x  106 cells/ml) was added to 
flat-bottom microtiter plates (A/S Nunc), to which either 
100 fx 1 o f  medium or medium containing Escherichia coli 
LPS (Sigma) in various concentrations, or 0.5 f.ig/ml 
phytohemagglutinin (PHA) (Burroughs Wellcome, Re­
points from 25g, female Swiss Webster mice (Charles 
River Laboratories,  Wilmington, MA) that received an 
intraperitoneal injection 2 ¿¿g o f  Hu rTNF.
Measurement of TNF Concentration in Human 
Plasma
Plasma samples prepared from either citrated or hepa­
rinized blood from patients with febrile illnesses were 
tested for T N F  in the RIA.
RESULTS 
Validation and Specificity of the RIA for Human 
TNF
As shown in Figure 1, fractions o f  radiolabeled Hu 
rT N F  w'hich had the highest binding to anti-TNF were 
found in the first peak o f  eluting radioactivity, whereas 
the second peak contained the nonprecipitable free io­
dine. The fractions with greater than 85% of  precipitable 
radiolabel were pooled and used as radiolabeled T N F  in 
the RIA. The specific activity o f  this pool was approxi-
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Fig. 1. Gel filtration chromatography of the radiolabeled TNF 
on Sephadex G50. The square symbols represent the counts in 
5 n\ of each fraction. The closed circles represent the counts 
obtained in each fraction after incubation with anti-TNF anti­
serum and precipitation with polyethylene glycol/antirabbit IgG.
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Fig. 2. Functional and structural integrity of the radiolabeled 
TNF. Biological activity of the radiolabeled TNF (□ )  is com- 
pared with that of unlabeled Hu rTNF (Y ) on L929 cells. The 
insert shows autoradiography of SDS-polyacrylamide gel elec­
trophoresis of radiolabeled Hu rTNF. A single band is obtained 
at approximately 17 kD.
L O G I T
Fig. 4. Standard curves for the TNF RIA in BSA-buffer
( ■ ------- ■ )  and serum (O ----- O). The cpm of the standards are
converted into logit. The curve fit for these curves can be 
described as y = 64 .97x 10-0,35x for the curve in buffer 
(regression coefficient 0.98) and as y = 56.80 x 10“ °'50x for 
the curve in serum (regression coefficient 0.96). The sensitivity 
of the assays is less than 10 pg/ml (logit <2.94).
R E C IP R O C A L  A N T I B O D Y  T IT E R
Fig. 3. Titration of anti-TNF antiserum with radiolabeled TNF. 
The antigen antibody complexes were precipitated with poly­
ethylene glycol/antirabbit IgG. The results are expressed as 
percent of the total counts per min.
mately 10 ¡xCi/fig. SDS polyacrylamide gel electropho­
resis demonstrated the homogeneity o f  the pooled 
fractions o f  radiolabeled T N F  (Fig. 2, insert). The bio­
logical activity o f  the Hu rT N F  appeared not to have 
been affected by the labeling procedure (Fig. 2).
Titration o f  the antiserum with the pooled radiolabeled 
ligand is shown in Figure 3. A 41% precipitation with 
polyethylene glycol/anti rabbit IgG at an anti-TNF dilu­
tion o f  1:20,000  was detected and this dilution was cho­
sen for use in the subsequent RIAs.
Representative standard curves for T N F  in BSA-buffer 
and frozen-thawed human serum are shown in Figure 4. 
The standard curves in these fluids do not coincide,
which implies that standard curves should be generated 
not only in BSA-buffer, but also in relevant biological 
fluids. From these standard curves it can be seen that the 
sensitivity o f  the assay is <  10 pg/ml (95% confidence 
limit, 2 .9  logit). In more than 20 radioimmunoassays 
using radiolabeled T N F  that was iodinated at different 
occasions, the sensitivity in BSA-buffer was in the same 
order  o f  magnitude (between 3 and 78 pg/ml, median 11 
pg/ml).
The RIA for Hu T N F  did not show cross-reactivity 
with either 100 or 10 ng/ml human recombinant IL-1 ß; 
100 or 10 ng/ml human recombinant IL-1 a:; 1,000 or 
100 ng/ml human recombinant IL-2; 100 ng/ml human 
recombinant IL-6 , 1,000 or 100 U/ml human recombi­
nant interferon a ;  1,000 or 100 U/ml human recombinant 
interferon 7 ; 10 or 1 ng/ml human recombinant GM - 
CSF; 50, 5, 0 .5 ,  or 0.05 ng/ml lymphotoxin; 100 or 50 
ng/ml human C5a des arg; or 10, 5, 2 .5 ,  1.25, 0 .625, 
0.312, 0 .156, 0 .078, 0 .039, or 0 .020 ng/ml murine re­
combinant TNF.
Measurement of TNF Concentrations in Human 
MNC Lysates and Supernatants
W hen supernatants from 24-h cultures o f  peripheral 
blood M N C , either unstimulated or stimulated, were 
tested in both the RIA and bioassay, a good correlation 
was found (Fig. 5). Because o f  the different detection 
ranges o f  both assays (bioassay, 500-15 pg/ml; RIA,
2 ,000-10  pg/ml) these samples were tested in the sensi­
tive portion o f  either assay at various dilutions, and the 
data shown were calculated from the dilutions. Repeat-
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was found: 2 ng/ml T N F  with 1 ng/ml LPS up to 100 ng/ 
ml T N F  with 50 ng/ml LPS, and thereafter leveling off. 
The IL-1 (3 concentration in these supernatants measured 
in an RIA showed an increase from 0.2 ng/ml to 19 ng/ 
ml with the same concentrations o f  LPS. Concentrations 
o f  IL-1 a: increased from 0 .04  to 1 ng/ml (Fig. 6 ).
To investigate the intraindividual consistency o f  TN F 
production, human M N C  of  three donors isolated and 
cultured on three different days were incubated with 
medium alone, medium with 1 ng/ml LPS, and medium 
with 30 fig!ml PHA. These experiments show good con­
sistency for unstimulated and LPS stimulated cells but 
less so far PHA stimulation (Fig. 7).
Distribution of TNF Produced by MNC of a Cohort 
100000 of 50 Healthy Humans
B I O A S S A Y  ( P G / M L )
Fig. 5. Correlation between radioimmunoassay for TNF and 
the bioassay. The regression coefficient is 0.89.
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Fig. 6. Mean secretion of TNF, IL-1 (3 and a  by 2.5 x 106 
mononuclear cells of three donors after different dosages of 
LPS in vitro. The cells were cultured for 24 h. The bars repre­
sent standard error of the mean.
edly freezing and thaw'ing o f  the samples (up to three 
times) was found not to affect the results o f  the RIA.
Comparison of Amounts of TNF, IL-1 ¡3 and a 
Secreted by MNC
Next, the dose-effect relationship for LPS stimulation 
o f  peripheral blood M N C  was assessed in supernatants 
from cells o f  three normal donors, cultured for 24 h (Fig. 
6 ). A dose dependent increase o f  the T N F  production
The amount o f  T N F  produced by human M N C  in vitro 
was determined in a cohort o f  50 normal volunteers 
(laboratory personnel). We studied total T N F  production 
by measuring the combined supernatant and cell lysate 
material present after 24 h o f  incubation. The data are 
depicted in Figure 8 . With few exceptions, T N F  levels 
were below the lower detection limit without exogenous 
stimuli. The unstimulated M N C  show a narrow concen­
tration range o f  TNF. LPS-stimulation led to T N F  con­
centrations up to nearly 6 ng/ml (median 2 .0  ng/ml). In 
4 individuals, the T N F  concentrations were below detec­
tion level. With PHA as a stimulus, a wider distribution 
o f  T N F  concentrations was observed ( >  14 ng/ml). Only 
one T N F  determination was below detection level. Cul­
tures performed in the presence o f  indomethacin showed
40 -
30 -
Ü
20 -
10 -
0
0 DONORA
DONORB
n DONORC
i•  •  •  •  « ■ • • • •• • .  •  «• • • • • • * > . « • • • •  A A AAA Ad
NONE LPS
ADDITION TO CELLS
PHA
Fig. 7. The consistency of TNF production in vitro; 2.5 x 106 
mononuclear cells of 3 different donors were isolated and cul­
tured on three different days. The cells were cultured for 24 h 
in medium alone, in the presence of 1 ng LPS/ml or PHA 30 ¿¿g/ 
ml. Supernatants and cell lysates were collected and assayed. 
Results show the mean and standard deviation on three differ­
ent days.
TNF  
I L - 1  f t
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higher T N F  concentrations for approximately 75% of  the 
donors (Fig. 8). The differences in T N F  production in 
the presence o f  indomethacin were not significant for the 
unstimulated cells; however,  for both LPS- and PHA- 
stimulated cells, indomethacin significantly increased the 
amount o f  T N F  (p <  0 .005,  Wilcoxon matched-pairs 
signed-ranks, two-tailed).
The M N C  preparations after Ficoll Hypaque separa­
tion contained on average 19 .1 % (SD ±  10.7) m ono­
cytes. No correlation was found between the number o f  
monocytes and the amount o f  T N F  produced (data not 
shown).
Use of the RIA With Plasma Samples
To investigate whether we could recover T N F  from the 
circulation, we injected mice with Flu rT N F  intraperito- 
neally, and detected the appearance and clearance o f  Hu 
rT N F  in the plasma. An injection o f  2 ¿xg o f  human TNF, 
which is a nonlethal dose, produced a peak concentration 
o f  266 ng/ml after 12 min. After 15 min, the concentra­
tion had fallen to 127 ng/ml.
W hen plasma samples (with heparin or citrate) from 
patients with a variety o f  febrile illnesses (burns, septi­
cemia, Still’s disease, H odgkin’s disease) were added 
directly to the RIA, T N F  was not detected. We observed 
that in the presence o f  these acute-phase samples, precip- 
itable radioactivity was often greater than 100% of  the 
zero standard, suggesting enhanced binding o f  the radio­
label, even if the standard curves for these assays were 
performed in normal plasma. However,  in heparinized 
plasma samples o f  four patients with malaria, we were 
able to detect T N F  concentrations o f  274 +  SEM 45 pg/ 
ml.
DISCUSSION
Employing the modified chloramine T method of  ra­
diolabeling and selecting the highest binding fractions to 
the specific polyclonal anti-TNF, we report the develop­
ment o f  a sensitive and useful RIA. The process o f  
radiolabeling o f  the T N F  molecule does not degrade the 
molecule as demonstrated by SDS-polyacrylamide gel 
electrophoresis,  nor does it affect the bioactivity. Al­
though we have found a good correlation between the 
RIA and the bioassay for TNF, the RIA is clearly supe­
rior to the bioassay. The latter is more laborious and less 
specific than the RIA. Substances inhibiting or promoting 
growth or adherence o f  the L929 cells may lead to false- 
positive or false-negative results. Also factors, such as 
I L - 1/5, may synergize with T N F  and lead to increased 
cytotoxicity (Ikejima et al, unpublished results).
The RIA is particularly useful for the detection o f  T N F  
produced by cultured human monocytes and natural killer
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Fig. 8. Distribution of TNF production by 2.5 x 106 MNC of 50 
donors. Supernatants and cell lysates were collected after 24 h 
of culture in medium alone, in the presence of 0.5 ng/ml LPS 
or 30 ^g/ml PHA. The cultures were performed with ( + ) or 
without ( - )  indomethacin.
cells [13-15]. Using a solid-phase RIA for TNF, Cuturi 
et al recently reported that T  lymphocytes exposed to 
phorbol esters or calcium ionophore also produce T N F  
[15]. For studies like ours, in which lymphocytes are not 
separated from monocytes, it is important to know that 
the RIA does not detect the comparable lymphocyte prod­
uct, lymphotoxin (TN F j3), despite its structural homol­
ogy with T N F  (T N F a )  [16, 17]. In the experiments 
using PH A  as a stimulant, production o f  lymphotoxin 
could be expected to have occurred [15, 18].
The concentrations o f  T N F  produced in the cultures of  
the unstimulated human cells in our experiments show a 
narrow range, owing to strict measures to eliminate con­
taminating bacterial products (such as LPS) from re­
agents and culture media [12]. Incubation with 
indomethacin showed a slight but significant increase in 
the amount o f  T N F  produced by LPS- or PHA-stimulated
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cells, pointing to an inhibitory effect o f  products o f  the 
cyclooxygenase pathway.
Using the R I A s  to TNF, IL-1 o: and (3, we measured 
the concentrations o f  these three major cytokines secreted 
by human M N C  stimulated w'ith various doses o f  LPS. 
In a highly consistent fashion, the cells o f  the three 
donors secreted large amounts o f  T N F  and a tenfold 
lesser amount o f  IL-1 (3. The amount o f  IL-1 a  secreted 
was considerably low^er. If, however, total (ie., secreted 
and cell-associated) IL-1 ¡3 is compared with total TNF, 
the amount o f  IL-1 (3 is greater than the amount T N F  
(Endres et al, unpublished data). The explanation should 
be sought in differences in the molecular structure of  
T N F  and IL-1. T N F  has a prominent signal peptide for 
cleavage and transport [ 16], and thus the amount of  T N F  
secreted approximates the total amount of  T N F  pro­
duced. IL-1 is lacking a clear signal peptide [19], and 
this results in a variable amount o f  extracellular IL-1 
[20]. Since LPS only stimulates T N F  production from 
monocytes and not from T cells [ 15], it can be calculated 
from the numbers o f  monocyte that stimulation with LPS 
results in the secretion o f  up to 0.2 pg of  T N F  per 
monocyte in 24 h.
The experiments using the cells o f  50 different healthy 
donors demonstrate the normal distribution pattern of 
T N F  production in vitro. With LPS as a stimulant, the 
cells o f  10% of  the donors produce less than 0.5 ng/ml 
TNF, and the cells o f  most donors produce more than 1 
ng/ml. With PH A, even higher concentrations o f  T N F  
are found. It is conceivable that the greater amount of  
T N F  produced upon stimulation w'ith PHA is mediated 
via an effect on the lymphocyte. We have not been able 
to correlate the amount o f  T N F  produced to obvious 
characteristics such as sex, race, and age. Since these 
studies were performed over a period of  6 weeks, sea­
sonal influences can also be ruled out. The experiments 
performed to investigate the intra-individual consistency 
o f  T N F  production suggest that high and low responders 
with regard to T N F  production exist. Since the gene for 
T N F  is closely located to the genes for HLA [21], the 
linkage o f  HLA haplotypes to T N F  production should be 
investigated.
The results o f  the experiments in which Hu rT N F  was 
injected into mice suggest a slightly shorter half-life of  
human T N F  than the 10-min half-life found by Flick and 
Gifford with murine T N F  [22]. Detection of  T N F  in the 
circulation o f  patients is still a problem when plasma or 
serum samples are put directly in the RIA. Similar prob­
lems have been reported by Scuderi et al [23], who were 
also unable to detect T N F  in the majority o f  patients with 
infectious or neoplastic disease. Like them, we detected 
circulating T N F  in malaria. The detectability o f  T N F  in 
mice injected with human recombinant IL-1 and the ob­
servation that acute-phase plasma samples bind more
than 100% o f  the radiolabeled T N F  points to substances 
in the circulation o f  humans with various diseases that 
compete with anti-TNF for binding o f  the labeled TNF 
Studies are under way to separate T N F  from such sub­
stances. However,  the RIA is highly useful to measure 
T N F  in stimulated M N C  from humans, eg, in disease 
states, on drugs, and during cytokine treatment. At a 
more basic level, detection o f  immunoreactive T N F  in 
studies on cytokine interaction, and studies o f  how var­
ious agents affect T N F  synthesis and gene expression in 
vitro will help to clarify our understanding o f  the control 
o f  T N F  production.
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